Chardan
Chardan is an investment bank based in New York, established in 2017. The firm specializes in providing capital market and research services, with a focus on the healthcare sector. It has been involved in facilitating various financial transactions, including mergers and acquisitions. Notably, Chardan Healthcare Acquisition Corp., a special purpose acquisition company (SPAC) created by Chardan, engaged in a reverse merger with BiomX Ltd., highlighting the firm's active role in the healthcare industry. Through its services, Chardan aims to support companies in navigating the complexities of capital markets and achieving strategic growth.
Renovacor, Inc. is a preclinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, dedicated to developing gene therapies for cardiovascular diseases. Founded in 2013, the company focuses on innovative treatments for dilated cardiomyopathy (DCM), particularly cases caused by mutations in the BAG3 gene. This condition affects over 3 million individuals in the United States, with around 35,000 patients estimated to have BAG3 mutations, classifying it as an orphan disease. Patients with BAG3-associated DCM, often younger and experiencing faster disease progression, currently have limited treatment options, primarily consisting of standard heart failure care. Renovacor's lead program involves a recombinant adeno-associated virus (AAV)-based gene therapy aimed at replacing the defective BAG3 gene, which holds the potential to prevent disease progression and improve outcomes for this vulnerable patient population.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.